专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20080175846A1 ANTIBODIES AGAINST CANCER ANTIGEN TMEFF2 AND USES THEREOF 有权
标题翻译：反对癌症抗原TMEFF2的抗体及其用途
公开(公告)号：US20080175846A1
公开(公告)日：2008-07-24
申请号：US11855073
申请日：2007-09-13
申请人： Vinay Bhaskar , Agustin de la Calle , Debbie Law , Ingrid Caras , Vanitha Ramakrishnan , Richard Murray , Daniel Afar , David Powers
发明人： Vinay Bhaskar , Agustin de la Calle , Debbie Law , Ingrid Caras , Vanitha Ramakrishnan , Richard Murray , Daniel Afar , David Powers
IPC分类号： A61K39/395 , A61P35/00 , C12N5/00 , A61K39/38 , C07K16/00
CPC分类号： C07K16/3069 , A61K47/6817 , A61K47/6869 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/77
摘要： Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
摘要翻译：本文描述了可用于诊断和治疗癌症的方法和组合物。

2. 发明授权

US07288248B2 Antibodies against cancer antigen TMEFF2 and uses thereof 有权
标题翻译：针对癌抗原TMEFF2的抗体及其用途
公开(公告)号：US07288248B2
公开(公告)日：2007-10-30
申请号：US10383447
申请日：2003-03-07
申请人： Vinay Bhaskar , Agustin de la Calle , Debbie Law , Ingrid Caras , Vanitha Ramakrishnan , Richard Murray , Daniel Afar , David Powers
发明人： Vinay Bhaskar , Agustin de la Calle , Debbie Law , Ingrid Caras , Vanitha Ramakrishnan , Richard Murray , Daniel Afar , David Powers
IPC分类号： A61K39/395
CPC分类号： C07K16/3069 , A61K47/6817 , A61K47/6869 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/77
摘要： Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
摘要翻译：本文描述了可用于诊断和治疗癌症的方法和组合物。

3. 发明申请

US20070249689A1 Pre-mixed, ready-to-use pharmaceutical compositions 有权
标题翻译：预混合即用型药物组合物
公开(公告)号：US20070249689A1
公开(公告)日：2007-10-25
申请号：US11788076
申请日：2007-04-18
申请人： Michelle Duncan , Supriya Gupta , David Haas , Norma Stephens , Camellia Zamiri
发明人： Michelle Duncan , Supriya Gupta , David Haas , Norma Stephens , Camellia Zamiri
IPC分类号： A61K31/455
CPC分类号： A61K47/48969 , A61K9/0019 , A61K31/4422 , A61K31/455 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/40 , A61K47/6951 , B82Y5/00 , C08B37/0015 , C08L5/16 , A61K2300/00
摘要： Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.
摘要翻译：本文提供了尼卡地平或其药学上可接受的盐的即用型预混药物组合物和用于治疗心血管和脑血管病症的方法。

4. 发明授权

US07217797B2 Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis 有权
标题翻译：通过诱变改变抗体的FcRn结合亲和力或血清半衰期
公开(公告)号：US07217797B2
公开(公告)日：2007-05-15
申请号：US10687118
申请日：2003-10-15
申请人： Paul R. Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
发明人： Paul R. Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
IPC分类号： C12P21/08 , C12P21/06 , C12P21/04 , C07K16/00 , C12N15/00
CPC分类号： C07K16/082 , C07K16/00 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
摘要翻译：本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。

5. 发明申请

US20070059748A1 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer 审中-公开
公开(公告)号：US20070059748A1
公开(公告)日：2007-03-15
申请号：US11516476
申请日：2006-09-06
申请人： Daniel Afar , Natasha Aziz , Kurt Gish , Peter Hevezi , David Mack , Keith Wilson , Albert Zlotnik
发明人： Daniel Afar , Natasha Aziz , Kurt Gish , Peter Hevezi , David Mack , Keith Wilson , Albert Zlotnik
IPC分类号： C12Q1/68
CPC分类号： G01N33/574 , C12Q1/6886 , C12Q2600/136 , C12Q2600/158 , G01N33/5011
摘要： Described herein are genes whose expression are up-regulated or down-regulated in specific cancers. Related methods and compositions that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.

6. 发明申请

US20060286671A1 Efficient generation of expression cell lines through the use of scorable homeostatic reporter genes 审中-公开
标题翻译：通过使用可扫描的稳态报告基因，有效产生表达细胞系
公开(公告)号：US20060286671A1
公开(公告)日：2006-12-21
申请号：US11509177
申请日：2006-08-23
申请人： Robert DuBridge
发明人： Robert DuBridge
IPC分类号： C12N15/74 , C12N15/09
CPC分类号： C07K16/00 , C12N15/907 , C12N2800/30 , C12N2840/203 , C12Q1/6897
摘要： The present invention provides methods for site-specific recombination in a cell, as well as vectors which can be employed in such methods. The methods and vectors of the present invention can be used to obtain persistent gene expression in a cell and to modulate gene expression. One preferred method according to the invention comprises contacting a cell with a vector comprising an origin of replication functional in mammalian cells located between first and second recombining sites located in parallel. Another preferred method comprises, in part, contacting a cell with a vector comprising first and second recombining sites in antiparallel orientations such that the vector is internalized by the cell. In both methods, the cell is further provided with a site-specific recombinase that effects recombination between the first and second recombining sites of the vector.
摘要翻译：本发明提供了细胞中位点特异性重组的方法，以及可用于这些方法的载体。本发明的方法和载体可用于获得细胞中持续的基因表达并调节基因表达。根据本发明的一种优选方法包括使细胞与包含位于平行位于第一和第二重组位点之间的哺乳动物细胞中起作用的复制起点的载体接触。另一个优选的方法部分地包括使细胞与包含反平行取向的第一和第二重组位点的载体接触，使得载体被细胞内化。在两种方法中，细胞还提供了一种位点特异性重组酶，其实现载体的第一和第二重组位点之间的重组。

7. 发明申请

US20200041526A1 ANTIBODIES AND METHODS FOR THE DETECTION OF CELL DEATH 审中-公开
公开(公告)号：US20200041526A1
公开(公告)日：2020-02-06
申请号：US16514380
申请日：2019-07-17
申请人： PDL BIOPHARMA, INC.
发明人： Jeffrey Allan MILLER , Eddie Phillip JEFFRIES
IPC分类号： G01N33/68 , C07K16/18 , G01N33/543
摘要： Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbound or excess material; and detecting the signal from the detection moiety, wherein the signal is positively correlated with the presence of the CK18 protein fragment in the sample.

8. 发明申请

US20130338038A1 METHOD OF SCREENING COMPLEX PROTEIN LIBRARIES TO IDENTIFY ALTERED PROPERTIES 审中-公开
公开(公告)号：US20130338038A1
公开(公告)日：2013-12-19
申请号：US12340199
申请日：2008-12-19
申请人： Robert DuBridge , David Powers
发明人： Robert DuBridge , David Powers
IPC分类号： C40B30/06 , C40B40/02 , C40B40/10 , C40B50/06 , C40B40/08
CPC分类号： C12Q1/6883 , C12N15/1037 , C12Q2600/156 , C12Q2600/158 , C12Q2600/16
摘要： The invention provides methods of making designed and constructed protein (e.g., antibody) libraries and libraries resulting from the same.

9. 发明授权

US07846435B1 Humanized antibodies that recognize Verotoxin II and cell line producing same 有权
标题翻译：识别Verotoxin II和产生相同的细胞系的人源化抗体
公开(公告)号：US07846435B1
公开(公告)日：2010-12-07
申请号：US09700851
申请日：1999-05-19
申请人： Yoh-Ichi Matsumoto , Atsuchi Imaizumi , Tsuyoshi Kimura , Tae Takeda , Yoshifumi Takeda, legal representative , Man Sung Co , Maximiliano Vasquez
发明人： Yoh-Ichi Matsumoto , Atsuchi Imaizumi , Tsuyoshi Kimura , Tae Takeda , Man Sung Co , Maximiliano Vasquez
IPC分类号： A61K39/00 , A61K39/40 , A61K39/02
CPC分类号： C07K16/1232 , A61K38/00 , C07K2317/24 , C07K2319/00
摘要： The invention provides humanized antibodies that specifically bind to, and preferably, neutralize, verotoxin II (VT2). The antibodies are useful for treating patients suffering from, or at risk of suffering, toxic effects of verotoxin.
摘要翻译：本发明提供特异性结合并优选中和藜芦毒素II（VT2）的人源化抗体。该抗体可用于治疗患有或有风险的患有毒死蜱毒素的患者。

10. 发明申请

US20080260740A1 Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer 审中-公开
标题翻译：用于诊断，预后和癌症治疗的抗LFL2抗体
公开(公告)号：US20080260740A1
公开(公告)日：2008-10-23
申请号：US12138353
申请日：2008-06-12
申请人： Yongke ZHANG , Vanitha RAMAKRISHNAN , Debbie LAW
发明人： Yongke ZHANG , Vanitha RAMAKRISHNAN , Debbie LAW
IPC分类号： A61K39/395 , C12N5/06 , A61P43/00
CPC分类号： C07K16/30 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6889 , A61K2039/505 , C07K2317/77 , G01N33/57492
摘要： Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
摘要翻译：本文提供了特异的抗LFL2抗体组合物。这些抗体可用于癌症，特别是乳腺癌，头颈癌，肺癌，卵巢癌，胃癌和胰腺癌的诊断，预后，治疗监测和治疗。此外，本文提供抗LFL2抗体，其靶向LFL2细胞外结构域的蛋白水解切割后残留的LFL2残基。另外，本文提供了抗LFL2抗体，其靶向周围癌肿瘤的基质，其中所述基质靶向抗LFL2抗体破坏癌肿瘤周围基质的完整性，并且还使得基质对化学治疗剂和其它分子靶向肿瘤细胞的药物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式